Pui C-H, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185–96.
Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33(27):2938.
Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, De Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216–22.
Athale U, Siciliano S, Thabane L, Pai N, Cox S, Lathia A, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer. 2008;51(6):792–7.
Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–9.
Mateos M, Trahair T, Mayoh C, Barbaro P, Sutton R, Revesz T, et al. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Thromb Res. 2019;178:132–8.
Parasole R, Petruzziello F, Menna G, Mangione A, Cianciulli E, Buffardi S, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010;51(6):1063–71.
Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32(9):949.
Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313(8):815–23.
Mateos MK, Marshall GM, Barbaro PM, Quinn MCJ, George C, Mayoh C, et al. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. Haematologica. 2022;107(3):635–43. https://doi.org/10.3324/haematol.2020.268565.
Parasole R, Valsecchi MG, Silvestri D, Locatelli F, Barisone E, Petruzziello F, et al. Correspondence: osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP). Blood Cancer J. 2018;8(12):1–6.
Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000;34(3):200–5.
Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2007;49(5):634–9.
Schmiegelow K, Müller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res. 2017;6:444.
Rank CU, Wolthers BO, Grell K, Albertsen BK, Frandsen TL, Overgaard UM, et al. Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age. J Clin Oncol. 2020;38(2):145–54.
Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2014;14(1):61–70.
Frandsen TL, Heyman M, Abrahamsson J, Vettenranta K, Åsberg A, Vaitkeviciene G, et al. Complying with the European clinical trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial. Eur J Cancer. 2014;50(2):251–9.
Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231–9.
Vetsch J, Wakefield C, Robertson E, Trahair T, Mateos M, Grootenhuis M, et al. Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review. Qual Life Res. 2018;27(6):1431–43.
Fardell JE, Vetsch J, Trahair T, Mateos M, Grootenhuis M, Touyz L, et al. Health-related quality of life of children on treatment for acute lymphoblastic leukemia: a systematic review. Pediatr Blood Cancer. 2017;64(9):e26489.
Meeske K, Katz ER, Palmer SN, Burwinkle T, Varni JW. Parent proxy-reported health-related quality of life and fatigue in pediatric patients diagnosed with brain tumors and acute lymphoblastic leukemia. Cancer. 2004;101(9):2116–25.
Savage E, Riordan A, Hughes M. Quality of life in children with acute lymphoblastic leukaemia: a systematic review. Eur J Oncol Nurs. 2009;13(1):36–48.
Sung L, Yanofsky R, Klaassen RJ, Dix D, Pritchard S, Winick N, et al. Quality of life during active treatment for pediatric acute lymphoblastic leukemia. Int J Cancer. 2011;128(5):1213–20.
Eiser C, Davies H, Jenney M, Stride C, Glaser A. HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2006;46(1):35–9.
Peeters J, Meitert J, Paulides M, Wiener A, Beck J, Calaminus G, et al. Health-related quality of life (HRQL) in ALL-patients treated with chemotherapy only-a report from the late effects surveillance system in Germany. Klin Padiatr. 2009;221(3):156.
van Litsenburg RR, Huisman J, Pieters R, Verhaak C, Kaspers GJ, Gemke RJ. Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia. Support Care Cancer. 2014;22(12):3235–42.
Dupuis LL, Lu X, Mitchell HR, Sung L, Devidas M, Mattano LA Jr, et al. Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: a prospective, longitudinal study from the Children's oncology group. Cancer. 2016;122(7):1116–25.
Zheng DJ, Lu X, Schore RJ, Balsamo L, Devidas M, Winick NJ, et al. Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: a report from the Children's oncology group AALL0932 trial. Cancer. 2018;124(3):571–9.
Mitchell HR, Lu X, Myers RM, Sung L, Balsamo LM, Carroll WL, et al. Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: results of Children's oncology group study AALL0331. Int J Cancer. 2016;138(2):332–9.
Eiser C, Stride CB, Vora A, Goulden N, Mitchell C, Buck G, et al. Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: a cohort study. Pediatr Blood Cancer. 2017;64:e26615. https://doi.org/10.1002/pbc.26615.
Rensen N, Steur LMH, Grootenhuis MA, van Eijkelenburg NKA, van der Sluis IM, Dors N, et al. Parental functioning during maintenance treatment for childhood acute lymphoblastic leukemia: effects of treatment intensity and dexamethasone pulses. Pediatr Blood Cancer. 2020;67(11):e28697.
Mateos MK, Tulstrup M, Quinn MC, Tuckuviene R, Marshall GM, Gupta R, et al. Genome-wide association Meta-analysis of single-nucleotide polymorphisms and symptomatic venous thromboembolism during therapy for acute lymphoblastic leukemia and lymphoma in Caucasian children. Cancers. 2020;12(5):1285.
The National Health and Medical Research Council tARCaUA: National Statement on Ethical Conduct in Human Research 2007 (Updated 2018): National Health and Medical Research Council; 2007 (Updated 2018).
National Cancer Institute: DHHS. National Cancer Institute Common Terminology Criteria for Adverse Events v4. 0. NIH publication# 09–7473. 2009.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663–71.
Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's oncology group. Blood. 2006;108(4):1165–73.
Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240–50.
Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477–89.
Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's oncology group. Blood. 2008;111(5):2548–55.
Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175–81.
Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol. 2009;146(3):292–9.
Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206–14.
Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's oncology group. Blood. 2011;118(2):243–51.
Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27(7):1497–503.
Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's oncology group. Br J Haematol. 2013;162(6):792–801.
Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's oncology group study AALL0232. J Clin Oncol. 2016;34(20):2380–8.
Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, et al. A pilot study of intensified PEG-Asparaginase in high-risk acute lymphoblastic leukemia: Children's oncology group study AALL08P1. J Pediatr Hematol Oncol. 2016;38(6):409–17.
Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol; results from an international randomised study. Blood. 2018;132(Supplement 1):655.
Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s oncology group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36(29):2926–34.
Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of Children's oncology group trial AALL0331. J Clin Oncol. 2020;38(6):602–12.
Varni JW, Burwinkle TM, Katz ER, Meeske K, Dickinson P. The PedsQL™ in pediatric cancer: reliability and validity of the pediatric quality of life inventory™ generic core scales, multidimensional fatigue scale, and cancer module. Cancer. 2002;94(7):2090–106.
Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1(1):54.
Mitchell AJ, Baker-Glenn EA, Granger L, Symonds P. Can the distress thermometer be improved by additional mood domains? Part I. initial validation of the emotion thermometers tool. Psychooncology. 2010;19(2):125–33.
Mitchell AJ, Baker-Glenn EA, Park B, Granger L, Symonds P. Can the distress thermometer be improved by additional mood domains? Part II. What is the optimal combination of emotion thermometers? Psychooncology. 2010;19(2):134–40.
Harju E, Michel G, Roser K. A systematic review on the use of the emotion thermometer in individuals diagnosed with cancer. Psychooncology. 2019;28(9):1803–18.
Furlong W, Rae C, Feeny D, Gelber RD, Laverdiere C, Michon B, et al. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59(4):717–24.
Santoro N, Colombini A, Silvestri D, Grassi M, Giordano P, Parasole R, et al. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience. J Pediatr Hematol Oncol. 2013;35(5):348–55.
Badke C, Fleming A, Iqbal A, Khilji O, Parhas S, Weinstein J, et al. Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies. Pediatr Blood Cancer. 2016;63(4):723–6.
Rubnitz J, Relling M, Harrison P, Sandlund J, Ribeiro R, Rivera G, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leuk. 1998;12(8):1176–81.
Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340–7.
Strauss AJ, Su JT, Dalton VMK, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001;19(12):3066–72.
Samarasinghe S, Dhir S, Slack J, Iyer P, Wade R, Clack R, et al. Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2013;162(5):710–3.
Wolthers B, Frandsen TL, Abrahamsson J, Albertsen B, Helt L, Heyman M, et al. Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. Leukemia. 2017;31(2):325–32.
Nunns M, Mayhew D, Ford T, Rogers M, Curle C, Logan S, et al. Effectiveness of nonpharmacological interventions to reduce procedural anxiety in children and adolescents undergoing treatment for cancer: a systematic review and meta-analysis. Psychooncology. 2018;27(8):1889–99.
Landier W, Alice MT. Use of complementary and alternative medical interventions for the management of procedure-related pain, anxiety, and distress in pediatric oncology: an integrative review. J Pediatr Nurs. 2010;25(6):566–79.